Diseases of the Musculoskeletal System, Phase II-III
Study to Assess the Efficacy and Safety of Setrusumab in Participants With Osteogenesis Imperfecta
Volunteers
Health Professionals
What is the purpose of this trial?
The primary objectives of the study are to identify a dose(s) of setrusumab based on safety and pharmacodynamic (PD) effects in participants with OI and to evaluate the effect of setrusumab vs placebo on reduction in total fracture rate.
- Trial withUltragenyx Pharmaceutical, Inc.
- Ages5 years - 25 years
- GenderBoth
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigator
- Last Updated01/25/2024
- Study HIC#2000031756